Why Novartis Keeps Writing Billion-Dollar Checks to This Biotech
Novartis just signed its second molecular glue deal with Orionis Biosciences, this time worth up to $1.4 billion in milestones. It's part of a Big Pharma spending spree on a technology that could crack open proteins nobody thought were druggable.
Six years ago, Orionis Biosciences didn't even have a public profile. The company slipped out of stealth in 2020 with a quiet Novartis partnership and a platform nobody outside the protein science world had heard of. Now Novartis just came back for seconds, and this time, the check has a lot more zeroes.
On June 10, Novartis and Orionis announced a second collaboration focused on molecular glue medicines. The deal: $40 million upfront to Orionis, with up to $1.4 billion in research, development, and commercial milestones, plus tiered royalties on any products that eventually hit the market. It's the kind of structure that says, "We like what we see, and we want more."
The question is: why?
The Superglue Strategy
To understand the hype, you need to understand molecular glues. Think of them like this: most drugs work by blocking a protein, like sticking a cork in a bottle. Molecular glues do something sneakier. They're tiny molecules that trick two proteins into sticking together, kind of like introducing two strangers at a party who instantly hit it off. That forced friendship can reprogram what a protein does, or better yet, flag it for destruction by the cell's own garbage disposal system.
This matters because a huge number of disease-causing proteins (some estimates say 80% or more) have no good "cork hole." They're flat, floppy, and resistant to traditional drugs. Scientists have spent decades calling them "undruggable." Molecular glues offer a workaround: instead of trying to block the unblockable, you change the game entirely.
Orionis built its Allo-Glue platform around a specific twist on this concept. Their glues work allosterically, meaning they change a protein's shape first, then force it into a new interaction. It's like bending a puzzle piece so it suddenly fits somewhere it never did before.
Why Novartis Came Back for More
The first Novartis-Orionis deal, signed in March 2020, was a four-year discovery collaboration with undisclosed financial terms. It included research funding, a convertible note investment, royalties, and milestone payments. At the time, Orionis was barely on anyone's radar.
Get tomorrow's biotech intelligence before your competitors.
Join thousands of biotech professionals who start their day with our free, daily briefing.
Since then, Orionis has been busy. The company dosed its first patient in a Phase 1 trial of ORB-011 (an engineered cytokine, not a glue) in advanced solid tumors by 2023. More importantly for this story, it landed a massive deal with Genentech in 2025 for molecular glue medicines in cancer, reportedly worth over $2 billion in potential milestones plus royalties, with an upfront payment of $105 million.
So when Novartis showed up again in June 2026, it wasn't a shot in the dark. It was a calculated decision to lock in more access to a platform that Genentech had already validated with its own big bet. The new collaboration will use Orionis' Allo-Glue technology and an AI-driven discovery engine to find and optimize molecular glues for "challenging therapeutic targets across multiple disease areas."
Translation: the hard stuff. The proteins nobody else can touch.
The Billion-Dollar Biobucks Game
Before anyone gets too excited about $1.4 billion, a reality check. That number is what the industry calls "biobucks," meaning it's the maximum Orionis could earn if every single program hits every research, clinical, and commercial milestone. Think of it like a real estate listing that says "potential ocean view": technically possible, but a lot has to go right.
The $40 million upfront is the real cash-in-hand figure. And in context, it's modest. Novartis paid $120 million upfront to Monte Rosa Therapeutics for a related (but more asset-specific) molecular glue degrader deal worth up to $5.7 billion in total milestone potential. The Orionis deal is structured more as a broad discovery engine play: less money per program, but potentially more programs.
For Orionis, the economics still work beautifully. The company now has two top-five pharma partners writing checks, funding its research, and taking on the expensive late-stage development work. Orionis focuses on discovery and optimization; Novartis handles the clinical trials, regulatory filings, and commercialization. It's the biotech equivalent of writing the recipe and letting someone else run the restaurant.
Big Pharma's Molecular Glue Shopping Spree
Novartis isn't alone in its obsession. The molecular glue and protein degradation space has become one of biopharma's most active dealmaking arenas, with a who's-who of Big Pharma scrambling to secure platform access.
Gilead paid $45 million to exercise an option on Kymera Therapeutics' KT-200. Roche expanded its partnership with C4 Therapeutics around degrader-antibody conjugates, reportedly paying $20 million upfront with over $1 billion in milestones. Amgen scooped up Dark Blue Therapeutics for up to $840 million. Meanwhile, Neomorph has racked up collaborations with Biogen, Novo Nordisk, and AbbVie.
The pattern is clear: Big Pharma is hedging its bets by partnering with multiple platform companies simultaneously. Nobody knows which approach will win, so everyone is buying a seat at every table. Novartis alone now has major molecular glue deals with both Monte Rosa and Orionis, each offering a different angle on the same fundamental science.
The Risks Nobody's Talking About
For all the excitement, molecular glue discovery remains genuinely hard. Historically, the biggest glue successes (like the cancer drugs thalidomide derivatives lenalidomide and pomalidomide) were discovered by accident. Building glues rationally, on purpose, at scale? That's the promise of platforms like Allo-Glue, but it's still largely unproven in the clinic for novel targets.
Orionis is betting that AI and systematic ligase profiling can turn what used to be serendipity into a repeatable process. Novartis is betting that Orionis is right. And the $40 million upfront, while real money, is small enough that Novartis can walk away without much damage if the science doesn't pan out.
That's the beauty of the biobucks structure: it aligns incentives perfectly. Orionis gets funded. Novartis gets optionality. And the big payouts only come if the drugs actually work.
What This Really Signals
Zoom out, and the Novartis-Orionis deal tells a bigger story. The pharmaceutical industry is making a collective bet that protein modulation (glues, degraders, conformational modulators) will be the next major wave of drug development, following small molecules and biologics. Transcription factors, signaling proteins, and other "undruggable" targets are suddenly in play.
We're already seeing early proof. Belzutifan, a direct inhibitor of the transcription factor HIF-2α, was approved in 2021 for a rare kidney cancer. PROTAC degraders targeting estrogen and androgen receptors are in late-stage trials. STAT6 degraders have entered first-in-human studies.
The molecular glue corner of this revolution is still earlier stage, which is exactly why deals like this one matter. They're not about products on pharmacy shelves tomorrow. They're about building the infrastructure, the platforms, and the know-how for the drugs of 2030 and beyond.
Novartis clearly thinks Orionis has something special. Two deals, six years apart, with escalating financial commitments, tell a story that press releases alone can't. Sometimes the smartest move in pharma isn't making the drug yourself; it's finding the people who can make the tools to find the drugs nobody else can.
Clinical & Regulatory4 min read
The Pentagon Just Dropped a Bomb on Biotech's Favorite Supplier
The Pentagon just labeled WuXi AppTec a "Chinese military company," and the ripple effects could force hundreds of biotech and pharma companies to rethink how their drugs get made. The world's largest CDMO is now at the center of a geopolitical earthquake.
